Zyprexa

Country: Европска Унија

Језик: Енглески

Извор: EMA (European Medicines Agency)

Купи Сада

Активни састојак:

olanzapine

Доступно од:

Eli Lilly Nederland B.V.

АТЦ код:

N05AH03

INN (Међународно име):

olanzapine

Терапеутска група:

Psycholeptics

Терапеутска област:

Schizophrenia; Bipolar Disorder

Терапеутске индикације:

Coated tabletsAdultsOlanzapine is indicated for the treatment of schizophrenia.Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.Olanzapine is indicated for the treatment of moderate to severe manic episode.In patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder.InjectionAdultsZyprexa powder for solution for injection is indicated for the rapid control of agitation and disturbed behaviours in patients with schizophrenia or manic episode, when oral therapy is not appropriate. Treatment with Zyprexa powder for solution for injection should be discontinued and the use of oral olanzapine should be initiated as soon as clinically appropriate.

Резиме производа:

Revision: 42

Статус ауторизације:

Authorised

Датум одобрења:

1996-09-27

Информативни летак

                                60
B. PACKAGE LEAFLET
61
PACKAGE LEAFLET: INFORMATION FOR THE USER
ZYPREXA 2.5 MG COATED TABLETS
ZYPREXA 5 MG COATED TABLETS
ZYPREXA 7.5 MG COATED TABLETS
ZYPREXA 10 MG COATED TABLETS
ZYPREXA 15 MG COATED TABLETS
ZYPREXA 20 MG COATED TABLETS
olanzapine
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
•
Keep this leaflet. You may need to read it again.
•
If you have any further questions, ask your doctor or pharmacist.
•
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
•
If you get any side effects talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What ZYPREXA is and what it is used for
2.
What you need to know before you take ZYPREXA
3.
How to take ZYPREXA
4.
Possible side effects
5.
How to store ZYPREXA
6.
Contents of the pack and other information
1.
WHAT ZYPREXA IS AND WHAT IT IS USED FOR
ZYPREXA contains the active substance olanzapine. ZYPREXA belongs to a
group of medicines
called antipsychotics and is used to treat the following conditions:
•
Schizophrenia, a disease with symptoms such as hearing, seeing or
sensing things which are not
there, mistaken beliefs, unusual suspiciousness, and becoming
withdrawn. People with this
disease may also feel depressed, anxious or tense.
•
Moderate to severe manic episodes, a condition with symptoms of
excitement or euphoria.
ZYPREXA has been shown to prevent recurrence of these symptoms in
patients with bipolar disorder
whose manic episode has responded to olanzapine treatment.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE ZYPREXA
_ _
DO NOT TAKE ZYPREXA
•
If you are allergic (hypersensitive) to olanzapine or any of the other
ingredients of this medicine
(listed in section 6).
An allergic reaction may be recognised as a rash, itching, a swollen
face,
swollen lips or shortness of breath. If this 
                                
                                Прочитајте комплетан документ
                                
                            

Карактеристике производа

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
ZYPREXA 2.5 mg coated tablets
ZYPREXA 5 mg coated tablets
ZYPREXA 7.5 mg coated tablets
ZYPREXA 10 mg coated tablets
ZYPREXA 15 mg coated tablets
ZYPREXA 20 mg coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
ZYPREXA 2.5 mg coated tablets
Each coated tablet contains 2.5 mg olanzapine.
Excipient with known effect: Each coated tablet contains 102 mg
lactose monohydrate.
ZYPREXA 5 mg coated tablets
Each coated tablet contains 5 mg olanzapine.
Excipient with known effect: Each coated tablet contains 156 mg
lactose monohydrate.
ZYPREXA 7.5 mg coated tablets
Each coated tablet contains 7.5 mg olanzapine.
Excipient with known effect: Each coated tablet contains 234 mg
lactose monohydrate.
ZYPREXA 10 mg coated tablets
Each coated tablet contains 10 mg olanzapine.
Excipient with known effect: Each coated tablet contains 312 mg
lactose monohydrate.
ZYPREXA 15 mg coated tablets
Each coated tablet contains 15 mg olanzapine.
Excipient with known effect: Each coated tablet contains 178 mg
lactose monohydrate.
ZYPREXA 20 mg coated tablets
Each coated tablet contains 20 mg olanzapine.
Excipient with known effect: Each coated tablet conatins 238 mg
lactose monohydrate.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Coated tablet
ZYPREXA 2.5 mg coated tablets
Round, white, coated tablets
_ _
imprinted with “LILLY” and a numeric identicode “4112”.
ZYPREXA 5 mg coated tablets
Round, white, coated tablets
_ _
imprinted with “LILLY” and a numeric identicode “4115”.
ZYPREXA 7.5 mg coated tablets
Round, white, coated tablets
_ _
imprinted with “LILLY” and a numeric identicode “4116”.
3
ZYPREXA 10 mg coated tablets
Round, white, coated tablets
_ _
imprinted with “LILLY” and a numeric identicode “4117”.
ZYPREXA 15 mg coated tablets
Elliptical, blue, coated tablets
_ _
debossed with “LILLY” and a numeric identicode “4415”.
ZYPREXA 20 mg coated tablets
Pink, elliptical, coated tablets
_ 
                                
                                Прочитајте комплетан документ
                                
                            

Документи на другим језицима

Информативни летак Информативни летак Бугарски 26-02-2024
Информативни летак Информативни летак Шпански 26-02-2024
Информативни летак Информативни летак Чешки 26-02-2024
Информативни летак Информативни летак Дански 26-02-2024
Информативни летак Информативни летак Немачки 26-02-2024
Информативни летак Информативни летак Естонски 26-02-2024
Информативни летак Информативни летак Грчки 26-02-2024
Информативни летак Информативни летак Француски 26-02-2024
Карактеристике производа Карактеристике производа Француски 26-02-2024
Информативни летак Информативни летак Италијански 26-02-2024
Карактеристике производа Карактеристике производа Италијански 26-02-2024
Извештај о процени јавности Извештај о процени јавности Италијански 03-07-2013
Информативни летак Информативни летак Летонски 26-02-2024
Информативни летак Информативни летак Литвански 26-02-2024
Карактеристике производа Карактеристике производа Литвански 26-02-2024
Информативни летак Информативни летак Мађарски 26-02-2024
Информативни летак Информативни летак Мелтешки 26-02-2024
Информативни летак Информативни летак Холандски 26-02-2024
Карактеристике производа Карактеристике производа Холандски 26-02-2024
Информативни летак Информативни летак Пољски 26-02-2024
Информативни летак Информативни летак Португалски 26-02-2024
Карактеристике производа Карактеристике производа Португалски 26-02-2024
Извештај о процени јавности Извештај о процени јавности Португалски 03-07-2013
Информативни летак Информативни летак Румунски 26-02-2024
Информативни летак Информативни летак Словачки 26-02-2024
Информативни летак Информативни летак Словеначки 26-02-2024
Карактеристике производа Карактеристике производа Словеначки 26-02-2024
Извештај о процени јавности Извештај о процени јавности Словеначки 03-07-2013
Информативни летак Информативни летак Фински 26-02-2024
Информативни летак Информативни летак Шведски 26-02-2024
Информативни летак Информативни летак Норвешки 26-02-2024
Информативни летак Информативни летак Исландски 26-02-2024
Карактеристике производа Карактеристике производа Исландски 26-02-2024
Информативни летак Информативни летак Хрватски 26-02-2024

Обавештења о претрази у вези са овим производом

Погледајте историју докумената